within Pharmacolibrary.Drugs.ATC.R;

model R01AD08
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.8333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.318,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R01AD08</td></tr><td>route:</td><td>intranasal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fluticasone is a synthetic corticosteroid with potent anti-inflammatory properties. It is commonly used as a nasal spray for the treatment of allergic rhinitis and as an inhaled medication for asthma and chronic obstructive pulmonary disease (COPD). Fluticasone is approved and widely used today in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following intranasal administration of fluticasone propionate.</p><h4>References</h4><ol><li><p>Szefler, SJ (2001). Pharmacokinetics of intranasal corticosteroids. <i>The Journal of allergy and clinical immunology</i> 108(1 Suppl) S26–S31. DOI:<a href=&quot;https://doi.org/10.1067/mai.2001.115563&quot;>10.1067/mai.2001.115563</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11449203/&quot;>https://pubmed.ncbi.nlm.nih.gov/11449203</a></p></li><li><p>Allen, A, et al., &amp; Miller, SR (2016). Pharmacokinetics, Safety, and Tolerability of Once-Daily Intranasal Fluticasone Furoate and Levocabastine Administered Alone or Simultaneously as fluticasone Furoate/Levocabastine Fixed-Dose Combination. <i>Clinical pharmacology in drug development</i> 5(3) 225–231. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.218&quot;>10.1002/cpdd.218</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27163502/&quot;>https://pubmed.ncbi.nlm.nih.gov/27163502</a></p></li><li><p>Bryson, HM, &amp; Faulds, D (1992). Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. <i>Drugs</i> 43(5) 760–775. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199243050-00009&quot;>10.2165/00003495-199243050-00009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1379151/&quot;>https://pubmed.ncbi.nlm.nih.gov/1379151</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R01AD08;
